BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36216975)

  • 1. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
    Santoro N; Mooyaart JE; Devillier R; Koc Y; Vydra J; Castagna L; Gülbas Z; Martin JD; Araujo MC; Kulagin A; Arat M; Arroyo CH; Martelli MP; Di Ianni M; Hoogenboom JD; de Wreede LC; Ruggeri A; Chabannon C
    Bone Marrow Transplant; 2023 Jan; 58(1):54-60. PubMed ID: 36216975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.
    Rampotas A; Sockel K; Panitsas F; Theuser C; Bornhauser M; Hernani R; Hernandez-Boluda JC; Esquirol A; Avenoso D; Tsirigotis P; Robin M; Czerw T; Helbig G; Roddie C; Lambert J; McLornan DP
    Transplant Cell Ther; 2023 Nov; 29(11):687.e1-687.e7. PubMed ID: 37633414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy.
    Goldsmith SR; Slade M; DiPersio JF; Westervelt P; Schroeder MA; Gao F; Romee R
    Bone Marrow Transplant; 2017 Dec; 52(12):1623-1628. PubMed ID: 29035393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Yang L; Lai X; Yang T; Lu Y; Liu L; Shi J; Zhao Y; Wu Y; Chen Y; Yu J; Xiao H; Ouyang G; Ren J; Cao J; Hu Y; Tan Y; Ye Y; Cai Z; Xu W; Huang H; Luo Y
    Bone Marrow Transplant; 2024 Jan; 59(1):85-92. PubMed ID: 37907756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD.
    He F; Warlick E; Miller JS; MacMillan M; Verneris MR; Cao Q; Weisdorf D
    Bone Marrow Transplant; 2016 Aug; 51(8):1107-12. PubMed ID: 27064686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant.
    Hou MH; Lee CY; Ho CY; Yu TY; Hung GY; Huang FL; Chiou TJ; Liu CY; Yen HJ
    J Chin Med Assoc; 2023 Nov; 86(11):991-1000. PubMed ID: 37697465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation.
    Harada K
    Int J Hematol; 2023 Aug; 118(2):158-168. PubMed ID: 37014602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.
    Harada K; Mizuno S; Yano S; Takami A; Ishii H; Ikegame K; Najima Y; Kako S; Ashida T; Shiratori S; Ota S; Onizuka M; Fukushima K; Fukuda T; Ichinohe T; Atsuta Y; Yanada M
    Ann Hematol; 2022 Mar; 101(3):643-653. PubMed ID: 34988692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
    Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.
    Bar M; Flowers MED; Storer BE; Chauncey TR; Pulsipher MA; Thakar MS; Bethge W; Storb R; Maloney DG; Sandmaier BM
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):308-313. PubMed ID: 29032276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
    Lu N; Lin J; Wang LL; Li YY; Wang LJ; Gao CJ; Liu DH; Gao XN
    Int J Hematol; 2022 May; 115(5):713-727. PubMed ID: 35128587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.
    Jaiswal SR; Zaman S; Chakrabarti A; Sen S; Mukherjee S; Bhargava S; Ray K; O'Donnell PV; Chakrabarti S
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1867-1873. PubMed ID: 27470289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
    Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
    Front Immunol; 2020; 11():191. PubMed ID: 32117310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
    van Gorkom G; van Gelder M; Eikema DJ; Blok HJ; van Lint MT; Koc Y; Ciceri F; Beelen D; Chevallier P; Selleslag D; Blaise D; Foá R; Corradini P; Castagna L; Moreno C; Solano C; Müller LP; Tischer J; Hilgendorf I; Hallek M; Bittenbring J; Theobald M; Schetelig J; Kröger N; ;
    Bone Marrow Transplant; 2018 Mar; 53(3):255-263. PubMed ID: 29255169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study.
    Lewalle P; Triffet A; Delforge A; Crombez P; Selleslag D; De Muynck H; Bron D; Martiat P
    Bone Marrow Transplant; 2003 Jan; 31(1):39-44. PubMed ID: 12621505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT.
    Dholaria B; Savani BN; Labopin M; Luznik L; Ruggeri A; Mielke S; Al Malki MM; Kongtim P; Fuchs E; Huang XJ; Locatelli F; Aversa F; Castagna L; Bacigalupo A; Martelli M; Blaise D; Ben Soussan P; Arnault Y; Handgretinger R; Roy DC; O'Donnell P; Bashey A; Solomon S; Romee R; Lewalle P; Gayoso J; Maschan M; Lazarus HM; Ballen K; Giebel S; Baron F; Ciceri F; Esteve J; Gorin NC; Spyridonidis A; Schmid C; Ciurea SO; Nagler A; Mohty M
    Haematologica; 2020 Jan; 105(1):47-58. PubMed ID: 31537691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.